NETSPOT DIN 02490005
Health Canada record
| Active ingredient(s) | OXODOTREOTIDE 40 MCG |
|---|---|
| Dosage form | Kit; Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09I TUMOUR DETECTION |
| Original market date | 18-Mar-2020 |
| Current status date | 28-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32789 | 2024-02-28 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 22356 | 2019-07-03 | New Drug Submission (NDS) |
International API supply for OXODOTREOTIDE
1 active FDA Drug Master Files.
Request a quote for NETSPOT